[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epilepsy-drug-resistant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epilepsy-drug-resistant":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,81,105,132,154,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100645320","non-invasive-low-intensity-focused-ultrasound-stimulation-for-drug-resistant-epilepsy-100645320",false,"NCT07680842","Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy","Pilot Study of Non-Invasive Low Intensity Focused Ultrasound as an Adjunctive Treatment for Drug-Resistant Epilepsy","Inclusion Criteria\n\n* Male or female between 21 and 65 years of age at screening\n* Clinical diagnosis of drug-resistant epilepsy with on average, 4 or more seizures per month.\n* Able to provide informed consent (or assent when applicable) by the subject or subject's legal representative.\n* Be willing to undergo a brain MRI.\n* Be able and willing to wear a headband during the treatment duration.\n* Be able to complete scheduled visits and daily seizure logs.\n\nExclusion Criteria\n\n* Has a craniotomy or pathologic intracranial lesion (e.g. vascular malformations) in the trajectory of the focused ultrasound beam.\n* Pregnant, breastfeeding, is attempting pregnancy, or unwilling to practice birth control during participation in the study.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Has any unstable medical or psychiatric disease.\n* Any contraindications for completing a brain MRI scan.\n* Has evidence of any other clinically relevant neurological disorder at the time of screening, including Alzheimer's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis.","ALL","21 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to investigate the effects of a non-invasive, low intensity focused ultrasound (LIFU) stimulation on seizure frequency and the epileptogenic network in drug-resistant epilepsy. LIFU uses focused sound waves to modulate deep brain regions and to enable changes in brain network activity. Encephalography (EEG) and behavioral tasks will also be used to study how LIFU affects brain activity.",[27,28,29,30,31,32,33],"Drug-Resistant Epilepsy","Epilepsy","Epilepsy (Treatment Refractory)","Epilepsy Comorbidities","Epilepsy, Drug Resistant","Epilepsy, Generalized","Epilepsy, Focal",[35,27,28,36,37,38,39],"Seizures","Transcranial Ultrasound Stimulation","Focused ultrasound Stimulation","Electroencephalography (EEG)","Low Intensity Focused ultrasound (LIFU)","RECRUITING","2026-06-25",{"date":43,"type":44},"2026-07-02","ACTUAL",{"date":46,"type":44},"2025-07-09",{"date":48,"type":21},"2027-06-01",{"name":50,"class":51},"University of California, San Francisco","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":18,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100602826","piriform-cortex-electrical-stimulation-for-temporal-lobe-epilepsy-with-biliteral-hippocampus-sclerosis-100602826","NCT07128563","Piriform Cortex Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis","Inclusion Criteria:\n\n* Participants are between the ages of 14 -65 years of age\n* Refractory to anti-seizure medications (ASMs).\n* Persistence of disabling seizures at least 3 times per 3 months or greater, and once or more in recent 1 month.\n* After comprehensive preoperative evaluation, patients who are considered unsuitable for or refuse resection surgery, or those for whom the effects of epileptic focus resection and thermocoagulation surgery are not satisfactory.\n* Participants must have had a non-invasive video-EEG monitoring revealing seizure semiology and ictal EEG consistent with bilateral Temporal Lobe Epilepsy\n* Biliteral hippocampal atrophy on MRI T1 imaging with increased ipsilateral mesial signal on T2 imaging\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;\n* Psychogenic non-epileptic seizures within 12 months;\n* Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;\n* Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications;\n* IQ \\\u003C 55 or severe cognitive dysfunction, unable to complete the study;\n* Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);\n* Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty\u002Fhospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;\n* Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function;\n* Pregnant, or planning to pregnant within 2 years;\n* Participation in another clinical study within 3 months;\n* Not suitable for enrollment as assessed by the multidisciplinary team of the center.","14 Years",{"count":61,"type":21},5,[24],"The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of Piriform cortex as adjunctive therapy for reducing the frequency of seizures in drug-resistant temporal lobe epilepsy with bilateral hippocampal sclerosis",[31],[66,67,68,69,70],"Deep Brain Stimulation","Drug Resistant Epilepsy","Piriform cortex","Temporal lobe epilepsy with bilateral hippocampal sclerosis","Neuromodulation","NOT_YET_RECRUITING","2025-08-13",{"date":74,"type":44},"2025-08-19",{"date":76,"type":21},"2025-09-10",{"date":78,"type":21},"2027-08-01",{"name":80,"class":51},"Xuanwu Hospital, Beijing",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":18,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":52},"100535169","subthalamic-nucleus-electrical-stimulation-for-drug-resistant-focal-motor-epilepsy-100535169","NCT06248333","Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy","Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel-group Trial","STEM","Inclusion Criteria:\n\n* 14-65 years of age, inclusive, at Screening Visit.\n* Refractory to anti-seizure medications (ASMs).\n* Diagnosed with focal motor epilepsy, which meets the following items:\n\n  1. Seizure mainly presents as focal tonic, myoclonic, or primary motor seizure (including primary sensory seizure), with or without secondary bilateral tonic-clonic seizure.\n  2. After a comprehensive evaluation, the epileptogenic zone was presumed to predominantly involve the unilateral or bilateral central area (precentral gyrus, postcentral gyrus, and paracentral lobule) or supplementary motor area according to comprehensive presurgical evaluation.\n* Within 1 month prior to the Screening Visit (M-3), the following conditions are met:\n\n  1. At least 3 focal onset seizures (with or without secondary bilateral tonic-clonic seizure).\n  2. Subject is receiving at least one type of ASM\\[s\\], and the regimen has been stable (no addition or removal of ASM\\[s\\] \\[not counting brief rescue medicines such as benzodiazepines\\]; dose adjustments are permitted to ASM\\[s\\]).\n* Within the baseline period (3 months after the Screening Visit \\[M-3\\]), the following conditions are met:\n\n  1. The patient or their caregiver is capable of completing the seizure diary.\n  2. Seizure diary shows an average of 3 or more partial-onset seizures (with or without secondary bilateral tonic-clonic seizure) per month during the Baseline Period, with no more than 30 days between seizures.\n  3. The regimen of ASM\\[s\\] has been stable (no addition or removal of ASM\\[s\\] \\[not counting brief rescue medicines such as benzodiazepines\\]; dose adjustments are permitted to ASM\\[s\\]).\n* After comprehensive preoperative evaluation, patients who are considered unsuitable for or refuse resection surgery, or those for whom the effects of epileptic focus resection and thermocoagulation surgery are not satisfactory.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;\n* Seizures mainly present as complex motor seizures (e.g., hyperkinetic, automatisms, etc.);\n* Tonic-clonic status epilepticus within12 months;\n* Psychogenic non-epileptic seizures within 12 months;\n* Structural lesion of the subthalamic nucleus;\n* Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;\n* Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications;\n* IQ \\\u003C 55 or severe cognitive dysfunction, unable to complete the study;\n* Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);\n* Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty\u002Fhospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;\n* Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function;\n* Pregnant, or planning to pregnant within 2 years;\n* Participation in another clinical study within 3 months;\n* Not suitable for enrollment as assessed by the multidisciplinary team of the center.",{"count":90,"type":21},33,[24],"The primary objective of this research is to study the efficacy and safety of deep brain stimulation (DBS) of subthalamic nucleus (STN) as adjunctive therapy for reducing the frequency of seizures in drug-resistant focal motor epilepsy.",[31],[66,67,95,96],"Subthalamic Nucleus","Focal Motor Epilepsy","2025-07-12",{"date":99,"type":44},"2025-07-15",{"date":101,"type":44},"2024-02-14",{"date":103,"type":21},"2026-06-30",{"name":80,"class":51},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":52},"100571402","early-phase-1-sirolomus-adjuvant-treatment-of-focal-refractory-epilepsy-satfre-100571402","NCT06719791","Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)","The Safety and Efficacy Evaluation of Sirolomus as an Adjunctive Treatment for Focal Refractory Epilepsy: A Pilot Study","Inclusion Criteria:\n\n* 18-60 years of age.\n* Meet the 2017 International League Against Epilepsy (ILAE) diagnostic criteria for for focal seizures or focal seizures progressing to bilateral tonic-clonic seizures.\n* Diagnosed with refractory epilepsy, having used at least two AEDs without effectiveness for 2 years. No drug interaction between current AEDs and sirolomus, and a stable dose for at least 12 weeks prior to enrollment.\n* Seizure duration ≥1 minute, with accompanying sensory impairment.\n* At least 6 focal seizures within the 12 weeks preceding enrollment.\n* EEG or MRI\u002FCT results within the past 2 years, confirming the diagnosis of focal epilepsy.\n* The use of vagus nerve stimulation (VNS) and deep brain stimulation (DBS) is permitted, need to implant at least 5 months and stable for at least 12 weeks before enrollment.The parameters should keep unchanged until the end of the study.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations\n* Psychogenic non-epileptic seizures within 12 months;\n* Treatable causes of epilepsy (such as metabolic disorders, toxicity, infections, space occupying lesions, or identified genetic abnormalities)\n* Patients with only non-motor focal seizures, as classified by the 2017 ILAE.\n* Seizure clusters within the 12 months.\n* Tonic-clonic status epilepticus within12 months.\n* Free of major medical illnesses including:\n* Cerebrovascular events within the past 6 months, including cerebral infarction, cerebral hemorrhage, and transient ischemic attack, or those with progressive intracranial lesions.\n* Severe uncontrolled diseases, such as immunodeficiency disorders, liver or kidney diseases, acute infections, or advanced-stage tumors.\n* Severe cardiovascular or peripheral vascular diseases, such as those classified as NYHA Class III-IV, or those with malignant arrhythmias (e.g., Long QT syndrome, Brugada syndrome, and conduction block), or any other clinically significant electrocardiogram abnormalities, or who have had a myocardial infarction within the past 3 months before screening\n* Participants with a history of medical conditions or surgeries that, in the investigator's judgment, could affect the absorption, distribution, or metabolism of the study drug (e.g., active peptic ulcers, ulcerative colitis, Crohn's disease, or bowel obstruction) or those with difficulty swallowing.\n* Participants with any medical condition, mental health status, cognitive impairment, or intellectual disability that the investigator believes could increase the risk to the participant or interfere with their ability to participate in the clinical trial.\n* Severe allergic reactions to any component of sirolimus, or have hypersensitivity.\n* Participants meeting any of the following laboratory criteria: alanine aminotransferase (ALT) \\>2× upper limit of normal (ULN), aspartate aminotransferase (AST) \\>2× ULN, alkaline phosphatase (ALP) \\>2× ULN, platelet count \\\u003C80×10\\^9\u002FL, neutrophil count \\\u003C1.8×10\\^9\u002FL, or creatinine clearance (CLcr) \\\u003C30 mL\u002Fmin (calculated by the Cockcroft-Gault formula).\n* In the period of pregnancy, childbirth, lactation.\n* Alcohol abuse or drug misuse within 2 years prior to medication.\n* Participation in another clinical study within 3 months;","18 Years","60 Years",{"count":115,"type":21},15,[117],"EARLY_PHASE1","The aim of this study is to evaluate the clinical efficacy of sirolimus as an adjunctive therapy for refractory epilepsy. The significance lies in addressing whether the mTOR inhibitor sirolimus has antiepileptic adjunctive effects for a broader range of patients with refractory epilepsy, with the hope of providing a new mTOR-targeted antiepileptic adjunctive medication regimen that is administered only during epileptic events and can be widely used for various types of refractory epilepsy.",[31],[121,122,123],"Sirolomus","Focal Refractory Epilepsy","mTOR pathway","2024-12-29",{"date":126,"type":44},"2024-12-31",{"date":128,"type":44},"2024-12-23",{"date":130,"type":21},"2028-12-01",{"name":80,"class":51},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":113,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":4},"100571403","early-phase-1-propranolol-adjuvant-treatment-of-focal-refractory-epilepsy-patfre-100571403","NCT06719804","Propranolol Adjuvant Treatment of Focal Refractory Epilepsy (PATFRE)","The Safety and Efficacy Evaluation of Propranolol as an Adjunctive Treatment for Focal Refractory Epilepsy: A Pilot Study","Inclusion Criteria:\n\n* 18-60 years of age.\n* Meet the 2017 International League Against Epilepsy (ILAE) diagnostic criteria for for focal seizures or focal seizures progressing to bilateral tonic-clonic seizures.\n* Diagnosed with refractory epilepsy, having used at least two AEDs without effectiveness for 2 years. No drug interaction between current AEDs and propranolol, and a stable dose for at least 12 weeks prior to enrollment.\n* Seizure duration ≥1 minute, with accompanying sensory impairment.\n* At least 6 focal seizures within the 12 weeks preceding enrollment.\n* EEG or MRI\u002FCT results within the past 2 years, confirming the diagnosis of focal epilepsy.\n* The use of vagus nerve stimulation (VNS) and deep brain stimulation (DBS) is permitted, need to implant at least 5 months and stable for at least 12 weeks before enrollment.The parameters should keep unchanged until the end of the study.\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations\n* Psychogenic non-epileptic seizures within 12 months;\n* Treatable causes of epilepsy (such as metabolic disorders, toxicity, infections, space-occupying lesions, or identified genetic abnormalities)\n* Patients with only non-motor focal seizures, as classified by the 2017 ILAE.\n* Seizure clusters within the 12 months.\n* Tonic-clonic status epilepticus within12 months.\n* Free of major medical illnesses including:\n* Cardiac diseases (history of cardiac valve disease, coronary artery disease, congestive heart failure, A-V block, peripheral vascular disease, any cardiac arrhythmia\u002Fbradycardia)\n* Histories of asthma, bronchospastic disease, or obstructive pulmonary disease\n* Severe allergic reactions to medications which are included in the beta blocker family\n* Currently treated with a beta adrenergic receptor antagonist or Previously used within 12 months\n* Uncontrolled Diabetes (HbA1c of ≤ 8 if previously tested)\n* Uncontrolled hypotension\n* Immunodeficiency disorders, liver or kidney diseases, acute infections, or advanced-stage tumors.\n* Participants with a history of medical conditions or surgeries that, in the investigator's judgment, could affect the absorption, distribution, or metabolism of the study drug (e.g., active peptic ulcers, ulcerative colitis, Crohn's disease, or bowel obstruction) or those with difficulty swallowing.\n* Participants with any medical condition, mental health status, cognitive impairment, or intellectual disability that the investigator believes could increase the risk to the participant or interfere with their ability to participate in the clinical trial.\n* Participants meeting any of the following laboratory criteria: alanine aminotransferase (ALT) \\>2× upper limit of normal (ULN), aspartate aminotransferase (AST) \\>2× ULN, alkaline phosphatase (ALP) \\>2× ULN, platelet count \\\u003C80×10\\^9\u002FL, neutrophil count \\\u003C1.8×10\\^9\u002FL, or creatinine clearance (CLcr) \\\u003C30 mL\u002Fmin (calculated by the Cockcroft-Gault formula).\n* In the period of pregnancy, childbirth, lactation.\n* Alcohol abuse or drug misuse within 2 years prior to medication.\n* Participation in another clinical study within 3 months;",{"count":115,"type":21},[117],"The aim of this study is to evaluate the clinical efficacy of propranolol as an adjunctive treatment for refractory epilepsy. The significance of this research lies in exploring whether propranolol, as an inhibitor of the CAMP-PKA-MEK\u002FERK pathway, can provide anticonvulsant effects for a wider range of refractory epilepsy patients. The study holds the potential to offer a novel adjunctive anticonvulsant treatment strategy targeting the CAMP-PKA-MEK\u002FERK pathway, specifically administered for seizure events, and applicable to various forms of refractory epilepsy.",[31],[144,122,145,146],"Propranolol","CAMP-PKA-MEK\u002FERK pathway","non-selective beta-adrenergic antagonists","2024-12-06",{"date":149,"type":44},"2024-12-10",{"date":151,"type":21},"2024-12-05",{"date":130,"type":21},{"name":80,"class":51},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":18,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":52},"100567049","extreme-capsule-electrical-stimulation-for-drug-resistant-focal-epilepsy-100567049","NCT06663124","Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy","Inclusion Criteria:\n\n* Participants are between the ages of 14 -65 years of age\n* Diagnosis of drug-resistant epilepsy follows the standard of resistance to regular medication treatment for at least two years. Comprehensive preoperative epilepsy assessment, combined with individualized fiber tracking, is used to determine whether the epileptogenic zone is located in cortex regions structurally connected to the extreme capsule.\n* Persistence of disabling seizures at least 3 times per month or greater,\n* Informed consent signed.\n\nExclusion Criteria:\n\n* Structural alterations are present in the extreme capsule.\n* Diagnosed with generalized or hereditary epilepsy with ion channel gene mutations;\n* Psychogenic non-epileptic seizures within 12 months;\n* Presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit;\n* Risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications;\n* IQ \\\u003C 55 or severe cognitive dysfunction, unable to complete the study;\n* Diagnosed with a progressive neurological disorder (including progressive Rasmussen's encephalitis, etc.);\n* Diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty\u002Fhospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders;\n* Diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function;\n* Pregnant, or planning to pregnant within 2 years;\n* Participation in another clinical study within 3 months;\n* Not suitable for enrollment as assessed by the multidisciplinary team of the center.",{"count":161,"type":21},10,[24],"Evaluation of the Efficacy and Safety of Deep Brain Stimulation of the Extreme Capsule (EC) for the Treatment of Drug-Resistant Epilepsy",[31],[166,66,67,167],"Extreme capsule","Focal Epilepsy","2024-10-27",{"date":170,"type":44},"2024-10-29",{"date":172,"type":21},"2024-11-01",{"date":174,"type":21},"2026-11-01",{"name":80,"class":51},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":52},"100544069","enhancing-epilepsy-management-with-precision-deep-brain-stimulation-100544069","NCT06364085","Enhancing Epilepsy Management With Precision Deep Brain Stimulation","EPI-BOOST: Enhancing Epilepsy Management With Precision Deep Brain Stimulation","EPI-BOOST","Inclusion Criteria:\n\n* Patients qualifying for deep brain stimulation on the basis of drug-resistant epilepsy\n* Informed consent\n\nExclusion Criteria:\n\n* Lack of consent\n* Electrical or other devices that preclude the performance of an MRI for pre-operative imaging",{"count":20,"type":21},[24],"The goal of this study is to evaluate the effectiveness of objective neural response feedback on deep brain stimulation (DBS) programming for drug-resistant epilepsy in a prospective observational cohort study.",[31],[189,190],"Deep brain stimulation","DBS Programming","2024-04-08",{"date":193,"type":44},"2024-04-15",{"date":195,"type":21},"2024-06",{"date":197,"type":21},"2026-06",{"name":199,"class":51},"Nova Scotia Health Authority"]